CJC-1295 (with DAC): Dosage, Protocol, and Research Guide
Long-acting growth hormone releasing hormone analog with Drug Affinity Complex for extended half-life
Mechanism
Modified GHRH analog with DAC technology that binds to albumin, extending half-life to 6-8 days. Continuously stimulates GHRH receptors in the pituitary, leading to sustained elevation of GH and IGF-1 levels.
Protocol at a glance
| Starting dose | 1mg |
|---|---|
| Maintenance dose | 1-2mg |
| Maximum dose | 2mg |
| Frequency | 1-2 times weekly |
| Typical duration | 3-6 month cycles |
| Route | Subcutaneous |
| Injection site | Abdomen or thigh |
| Timing | Before bed on empty stomach |
Side effects
- Injection site reactions
- Fatigue
- Flushing
- Possible water retention
- Vivid dreams
Contraindications
- Active cancer
- Pregnancy
- Severe organ dysfunction
Protocol notes
- Extended 6-8 day half-life due to DAC modification
- Weekly dosing provides sustained GH elevation
- Often combined with Ipamorelin for synergistic effects
- Monitor IGF-1 levels during therapy
- May cause more side effects than non-DAC version
Frequently asked questions
What is CJC-1295 (with DAC) and how does it differ from regular CJC-1295?
CJC-1295 (with DAC) is a long-acting growth hormone releasing hormone analog modified with Drug Affinity Complex technology. The DAC modification binds to albumin in the bloodstream, extending the peptide's half-life to 6-8 days—significantly longer than non-DAC versions. This allows sustained elevation of growth hormone and IGF-1 levels with less frequent injections (1-2 times weekly versus daily dosing). The extended half-life results in more consistent hormonal stimulation while requiring fewer injection sessions.
What is the typical dosing protocol for CJC-1295 research?
The typical starting dose of CJC-1295 (with DAC) is 1mg per injection. Maintenance dosing ranges from 1-2mg per injection, with a maximum of 2mg per injection. Most research protocols administer injections 1-2 times per week via subcutaneous injection into the abdomen or thigh. Research cycles typically last 3-6 months. Injections are traditionally timed before bed on an empty stomach to align with natural growth hormone secretion patterns.
How often should CJC-1295 (with DAC) be injected?
CJC-1295 (with DAC) is administered 1-2 times per week via subcutaneous injection. The extended 6-8 day half-life due to DAC modification allows for this infrequent dosing schedule while maintaining sustained elevation of growth hormone and IGF-1 levels. This weekly or twice-weekly schedule is one of the key advantages over non-DAC peptides, which typically require more frequent injections. Most research cycles span 3-6 months.
What are the side effects of CJC-1295 (with DAC)?
Common side effects documented in research include injection site reactions, fatigue, flushing, possible water retention, and vivid dreams. These are generally mild to moderate in nature. CJC-1295 (with DAC) may cause more side effects compared to non-DAC versions due to its prolonged activity and sustained hormone elevation. Contraindications include active cancer, pregnancy, and severe organ dysfunction. Any concerns about side effects should be discussed with a qualified healthcare provider.
Can CJC-1295 be stacked with other peptides?
Yes, CJC-1295 is frequently combined with other peptides in research protocols, most notably with Ipamorelin. Ipamorelin acts through a complementary mechanism to stimulate growth hormone release, and the combination is believed to produce synergistic effects on overall growth hormone elevation and potential metabolic benefits. Both peptides are administered via subcutaneous injection and are commonly part of comprehensive research protocols designed to maximize growth hormone stimulation.
What lab markers should be monitored during CJC-1295 research?
IGF-1 levels should be monitored during therapy with CJC-1295 (with DAC) to track response and ensure safety. IGF-1 is the primary marker of growth hormone activity and responsiveness, as growth hormone exerts many of its effects through IGF-1 production. Regular monitoring of IGF-1 helps researchers understand the peptide's effectiveness, assess individual response to the protocol, and informs decisions about dosing adjustments or protocol modifications.
How long does a typical CJC-1295 cycle last?
Most research cycles with CJC-1295 (with DAC) last 3-6 months. This duration provides sufficient time to observe meaningful changes in body composition, recovery markers, muscle development, and metabolic parameters. The exact length of a research cycle may vary based on individual research goals, baseline metrics, and response to the peptide.
What is the proper injection technique for CJC-1295?
CJC-1295 (with DAC) is administered via subcutaneous injection into the abdomen or thigh. The peptide is typically injected before bed on an empty stomach. This timing aligns with the body's natural nocturnal growth hormone secretion patterns and may enhance physiological response. Proper injection site rotation and sterile injection technique are important for minimizing injection site reactions and ensuring protocol safety.
More Growth Hormone Peptides peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.